Clatterbridge Hospital

The clinical features, age at onset and survival of 152 patients with von Hippel-Lindau disease were studied. Mean age at onset was 26.3 years and 97 per cent of patients had presented by aged 60 years. Retinal angioma was the first manifestation in 65 patients (43 per cent), followed by cerebellar haemangioblastoma (n = 60, 39 per cent) and renal cell carcinoma (n = 15, 10 per cent). Overall, 89 patients (59 per cent) developed a cerebellar haemangioblastoma, 89 (59 per cent) a retinal angioma, 43 (28 per cent) renal cell carcinoma, 20 (13 per cent) spinal haemangioblastoma and 11 (7 per cent) a phaeochromocytoma. Renal, pancreatic and epididymal cysts were frequent findings but their exact incidence was not accurately assessed. Mean age at diagnosis of renal cell carcinoma (44.0 +/- 10.9 years) was significantly older than that for cerebellar haemangioblastoma (29.0 +/- 10.0 years) and retinal angioma (25.4 +/- 12.7 years). The probability of a patient with von Hippel-Lindan disease developing a cerebellar haemangioblastoma, retinal angioma or renal cell carcinoma by age 60 years was 0.84, 0.7 and 0.69, respectively. A comprehensive screening protocol for affected patients and at-risk relatives is presented, based on detailed analysis of age at onset data for each of the major complications. Median actuarial survival was 49 years, with renal cell carcinoma the leading cause of death.

W. R. Gilks, N. G. Best, K. K. C. Tan, Adaptive Rejection Metropolis Sampling within Gibbs Sampling, Journal of the Royal Statistical Society. Series C (Applied Statistics), Vol. 44, No. 4 (1995), pp. 455-472

Groups of patients with dementia of Alzheimer type (DAT) and idiopathic Parkinson's disease, together with age and IQ-matched normal controls, were compared on several computerized tests of visuospatial memory and learning. Two different groups of parkinsonian patients were studied: (1) a newly diagnosed group, early in the course of the disease, not receiving medication (NMED PD) and (2) a group later in the course of the disease, receiving medication (MED PD). The DAT and MED PD group were significantly impaired in both spatial and visual pattern recognition memory. The DAT group exhibited a delay-dependent deficit (over 0–16 s) in a delayed matching-to-sample procedure, but were not impaired at simultaneous-matching-to-sample. By contrast, the MED PD group showed delay-independent deficits in the delayed matching-to-sample test and both the MED PD and the NMED PD group were also significantly impaired in simultancous matching. In a form of delayed response test, the subjects were required first to memorize and then to learn the locations of several abstract visual stimuli which varied progressively in number from 1 to 8. The DAT group were severely impaired in this conditional associative learning task. A significant proportion of patients, but none of the controls, in the NMED and MED PD group also failed the test at the levels of 6 or 8 items. There was a significant correlation between the performance on the first trial, memory score in the delayed response task and indices of clinical disability and disease duration in the patients with Parkinson's disease. The results are discussed in terms of the utility of the comparison between DAT and PD in characterizing the nature of the cognitive deficits in these conditions and their relation to those findings from animal neuropsychology which use comparable paradigms.

Tests which assess the ability to shift cognitive set modelled after the Wisconsin Card Sorting Test are particularly sensitive to impairments in patients with Parkinson's disease as well as in patients with frontal lobe damage. However, the underlying mechanisms responsible for the similar deficits observed in the two patient groups are not well understood and may not be identical. For example, an apparent deficit in set-shifting ability may reflect either an impairment in the ability to shift from a perceptual dimension which has previously commanded attention (i.e. 'perseveration'), or in the ability to shift to an alternative perceptual dimension which has previously been irrelevant (i.e. 'learned irrelevance'). In this study, the performance of both medicated and non-medicated patients with Parkinson's disease were compared with a group of neurosurgical patients with localized excisions of the frontal lobes on a novel task designed to assess the relative contribution of 'perseveration' and 'learned irrelevance' to impaired set-shifting ability. Patients with frontal lobe damage were worse than controls in their ability to shift attention from a previously relevant stimulus dimension. Medicated patients with Parkinson's disease were worse at shifting to a previously irrelevant dimension. In contrast to both groups, nonmedicated patients with Parkinson's disease were impaired in both conditions. These results suggest that the gross set-shifting deficits reported in both frontal lobe patients and patients with Parkinson's disease may involve fundamentally different, though related, cognitive processes, and that these may be differentially affected by medication. Specifically, L-dopa therapy may protect Parkinson's disease patients from preservation of attention to a formerly relevant stimulus dimension.

V.H., a 68-year-old right-handed woman, presented with a progressive deterioration in her ability to recognize faces of familiar people, including friends and relatives. Neuropsychological testing on two occasions separated by 9 months indicated no deterioration in general intellectual ability from estimates of her pre-morbid IQ (in the high average range), and little or no change in memory, language, perceptual or executive functioning. She is severely impaired on tests of face recognition and has shown some deterioration between testing occasions. In contrast, face perception skills, including emotional expression analysis, appear to be intact. Her knowledge of people from names was originally much better than from faces, but clearly declined on follow-up. This progression is discussed in the context of contemporary models of face processing: we suggest that her prosopagnosic deficit began as a modality-specific disorder which has progressed to a cross-modality loss of person-based semantic knowledge. In addition, she shows a striking dissociation between her ability to recognize faces and unique exemplars from other categories, such as buildings and flowers, which confirms the hypothesis that face processing is indeed special. Scanning by SPECT and MRI revealed selective hypoperfusion and atrophy, respectively, of the anterior part of the right temporal lobe. In recent years there have been a number of descriptions of progressive fluent aphasia resulting from atrophy of the left temporal lobe. This case appears to represent a corresponding degenerative process affecting the right temporal lobe.

UNLABELLED: The biochemical response to ursodeoxycholic acid (UDCA)--so-called "treatment response"--strongly predicts long-term outcome in primary biliary cholangitis (PBC). Several long-term prognostic models based solely on the treatment response have been developed that are widely used to risk stratify PBC patients and guide their management. However, they do not take other prognostic variables into account, such as the stage of the liver disease. We sought to improve existing long-term prognostic models of PBC using data from the UK-PBC Research Cohort. We performed Cox's proportional hazards regression analysis of diverse explanatory variables in a derivation cohort of 1,916 UDCA-treated participants. We used nonautomatic backward selection to derive the best-fitting Cox model, from which we derived a multivariable fractional polynomial model. We combined linear predictors and baseline survivor functions in equations to score the risk of a liver transplant or liver-related death occurring within 5, 10, or 15 years. We validated these risk scores in an independent cohort of 1,249 UDCA-treated participants. The best-fitting model consisted of the baseline albumin and platelet count, as well as the bilirubin, transaminases, and alkaline phosphatase, after 12 months of UDCA. In the validation cohort, the 5-, 10-, and 15-year risk scores were highly accurate (areas under the curve: >0.90). CONCLUSIONS: The prognosis of PBC patients can be accurately evaluated using the UK-PBC risk scores. They may be used to identify high-risk patients for closer monitoring and second-line therapies, as well as low-risk patients who could potentially be followed up in primary care.

Three hundred patients with symptomatic, locally advanced or metastatic NSCLC not requiring immediate radiotherapy were enrolled into this randomized multicentre trial comparing gemcitabine + BSC vs BSC alone. Patients allocated gemcitabine received 1000 mg/m2 on days 1, 8 and 15 of a 28-day cycle, for a maximum of six cycles. The main aim of this trial was to compare patient assessment of a predefined subset of commonly reported symptoms (SS14) from the EORTC QLQ-C30 and LC13 scales. The primary end-points were defined as (1) the percentage change in mean SS14 score between baseline and 2 months and (2) the proportion of patients with a marked (> or = 25%) improvement in SS14 score between baseline and 2 months sustained for > or =4 weeks. The secondary objectives were to compare treatments with respect to overall survival, and multidimensional QL parameters. The treatment groups were balanced with regard to age, gender, Karnofsky performance status (KPS) and disease stage (40% had metastatic disease). The percentage change in mean SS14 score from baseline to 2 months was a 10% decrease (i.e. improvement) for gemcitabine plus BSC and a 1% increase (i.e. deterioration) for BSC alone (P = 0.113, two-sample t-test). A sustained (> or = 4 weeks) improvement (> or =25%) on SS14 was recorded in a significantly higher proportion of gemcitabine + BSC patients (22%) than in BSC alone patients (9%) (P = 0.0014, Pearson's chi-squared test). The QLQ-C30 and L13 subscales showed greater improvement in the gemcitabine plus BSC arm (in 11 domains) than in the BSC arm (one symptom item). There was greater deterioration in the BSC alone arm (six domains/items) than in the gemcitabine + BSC arm (three QL domains). Tumour response occurred in 19% (95% CI 13-27) of gemcitabine patients. There was no difference in overall survival: median 5.7 months (95% CI 4.6-7.6) for gemcitabine + BSC patients and 5.9 months (95% CI 5.0-7.9) (log-rank, P = 0.84) for BSC patients, and 1 -year survival was 25% for gemcitabine + BSC and 22% for BSC. Overall, 74 (49%) gemcitabine + BSC patients and 119 (79%) BSC patients received palliative radiotherapy. The median time to radiotherapy was 29 weeks for gemcitabine + BSC patients and 3.8 weeks for BSC. Patients treated with gemcitabine + BSC reported better QL and reduced disease-related symptoms compared with those receiving BSC alone. These improvements in patient-assessed QL were significant in magnitude and were sustained.

BACKGROUND: Epigenetic silencing of O(6)-methylguanine-DNA-methyltransferase (MGMT) by promoter methylation is associated with improved survival in glioblastomas treated with alkylating agents. In this study, we investigated MGMT promoter methylation in glioblastomas treated with temozolomide and radiotherapy in a single UK treatment centre. METHODS: Quantitative methylation data at individual CpG sites were obtained by pyrosequencing for 109 glioblastomas. RESULTS: Median overall survival (OS) was 12.4 months with 2-year survival of 17.9%. Pyrosequencing data were reproducible with archival samples yielding data for all glioblastomas. Variation in methylation patterns of discrete CpG sites and intratumoral methylation heterogeneity were observed. A total of 58 out of 109 glioblastomas showed average methylation >non-neoplastic brain in at least one clinical sample; 86% had homogeneous methylation status in multiple samples. Methylation was an independent prognostic factor associated with prolonged progression-free survival (PFS) and OS. Cases with methylation more than 35% had the longest survival (median PFS 19.2; OS 26.2 months, 2-year survival of 59.7%). Significant differences in PFS were seen between those with intermediate or high methylation and unmethylated cases, whereas cases with low, intermediate or high methylation all showed significantly different OS. CONCLUSIONS: These data indicate that MGMT methylation is prognostically significant in glioblastomas given chemoradiotherapy in the routine clinic; furthermore, the extent of methylation may be used to provide additional prognostic stratification.

PURPOSE Previous studies of hypofractionated adjuvant whole-breast radiotherapy for early breast cancer established a 15- or 16-fraction (fr) regimen as standard. The FAST Trial (CRUKE/04/015) evaluated normal tissue effects (NTE) and disease outcomes after 5-fr regimens. Ten-year results are presented. METHODS Women ≥ 50 years of age with low-risk invasive breast carcinoma (pT1-2 pN0) were randomly assigned to 50 Gy/25 fr (5 weeks) or 30 or 28.5 Gy in 5 once-weekly fr of 6.0 or 5.7 Gy. The primary end point was change in photographic breast appearance at 2 and 5 years; secondary end points were physician assessments of NTE and local tumor control. Odds ratios (ORs) from longitudinal analyses compared regimens. RESULTS A total of 915 women were recruited from 18 UK centers (2004-2007). Five-year photographs were available for 615/862 (71%) eligible patients. ORs for change in photographic breast appearance were 1.64 (95% CI, 1.08 to 2.49; P = .019) for 30 Gy and 1.10 (95% CI, 0.70 to 1.71; P = .686) for 28.5 Gy versus 50 Gy. α/β estimate for photographic end point was 2.7 Gy (95% CI, 1.5 to 3.9 Gy), giving a 5-fr schedule of 28 Gy (95% CI, 26 to 30 Gy) estimated to be isoeffective with 50 Gy/25 fr. ORs for any moderate/marked physician-assessed breast NTE (shrinkage, induration, telangiectasia, edema) were 2.12 (95% CI, 1.55 to 2.89; P < .001) for 30 Gy and 1.22 (95% CI, 0.87 to 1.72; P = .248) for 28.5 Gy versus 50 Gy. With 9.9 years median follow-up, 11 ipsilateral breast cancer events (50 Gy: 3; 30 Gy: 4; 28.5 Gy: 4) and 96 deaths (50 Gy: 30; 30 Gy: 33; 28.5 Gy: 33) have occurred. CONCLUSION At 10 years, there was no significant difference in NTE rates after 28.5 Gy/5 fr compared with 50 Gy/25 fr, but NTE were higher after 30 Gy/5 fr. Results confirm the published 3-year findings that a once-weekly 5-fr schedule of whole-breast radiotherapy can be identified that appears to be radiobiologically comparable for NTE to a conventionally fractionated regimen.

A suppression subtractive cDNA library representing mRNAs expressed at a higher level in the malignant human breast cancer cell line, MCF-7, relative to a benign breast tumor-derived cell line, Huma 123, contained a cDNA, M36, which was expressed in estrogen receptor alpha (ERalpha)-positive breast carcinoma cell lines but not in cell lines from normal/benign/ERalpha-negative malignant breast lesions. M36 cDNA had an identical coding sequence to anterior gradient 2 (AGR2), the human homologue of the cement gland-specific gene (Xenopus laevis). Screening of breast tumor specimens using reverse transcription-PCR and immunocytochemistry with affinity-purified anti-AGR2 antibodies showed that the presence of AGR2 mRNA and protein were both statistically significantly associated with ERalpha-positive carcinomas (P = 0.007, Fisher's exact test) and with malignancy (P < or = 0.025). When an expression vector for AGR2 cDNA was introduced into benign nonmetastatic rat mammary tumor cells, and three separate clones and two pools of cells were transferred to the mammary glands of syngeneic hosts, there were no consistent differences in the mean latent periods of tumor formation. However, metastases occurred in the lungs of animals receiving the AGR2 transfectants in 77% to 92% of animals with primary tumors (P = 0.0001) compared with no metastases in the control groups. The AGR2 transfectants exhibited enhanced rates of adhesion to a plastic substratum and extracellular AGR2 enhanced the rate of attachment of AGR2-negative but not AGR2-positive cells. These experiments are the first to link mechanistically the developmental gene product, AGR2, with metastasis in vivo.

BACKGROUND: The National Epirubicin Adjuvant Trial (NEAT) and the BR9601 trial examined the efficacy of anthracyclines in the adjuvant treatment of early breast cancer. METHODS: In NEAT, we compared four cycles of epirubicin followed by four cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) with six cycles of CMF alone. In the BR9601 trial, we compared four cycles of epirubicin followed by four cycles of CMF, with eight cycles of CMF alone every 3 weeks. The primary end points were relapse-free and overall survival. The secondary end points were adverse effects, dose intensity, and quality of life. RESULTS: The two trials included 2391 women with early breast cancer; the median follow-up was 48 months. Relapse-free and overall survival rates were significantly higher in the epirubicin-CMF groups than in the CMF-alone groups (2-year relapse-free survival, 91% vs. 85%; 5-year relapse-free survival, 76% vs. 69%; 2-year overall survival, 95% vs. 92%; 5-year overall survival, 82% vs. 75%; P<0.001 by the log-rank test for all comparisons). Hazard ratios for relapse (or death without relapse) (0.69; 95% confidence interval [CI], 0.58 to 0.82; P<0.001) and death from any cause (0.67; 95% CI, 0.55 to 0.82; P<0.001) favored epirubicin plus CMF over CMF alone. Independent prognostic factors were nodal status, tumor grade, tumor size, and estrogen-receptor status (P<0.001 for all four factors) and the presence or absence of vascular or lymphatic invasion (P=0.01). These factors did not significantly interact with the effect of epirubicin plus CMF. The overall incidence of adverse effects was significantly higher with epirubicin plus CMF than with CMF alone but did not significantly affect the delivered-dose intensity or the quality of life. CONCLUSIONS: Epirubicin plus CMF is superior to CMF alone as adjuvant treatment for early breast cancer. (ClinicalTrials.gov number, NCT00003577 [ClinicalTrials.gov].).

OBJECTIVE: To assess dose-response relationships to a single dose of botulinum toxin 'A' in upper limb spasticity associated with stroke or head injury. DESIGN: A double-blind placebo-controlled randomized dose ranging study. SETTING: A regional centre for neuroscience and a neurorehabilitation outpatient clinic. SUBJECTS: Twenty-one hemiplegic patients with troublesome upper limb spasticity. Nineteen with stroke and two with head injury. MAIN OUTCOME MEASURES: Spasticity (modified Ashworth), range of movement, posture (postural alignment and finger curl), disability (upper body dressing time and Frenchay Arm Test), patient-reported global assessment scale. RESULTS: Combining data from all doses of botulinum toxin there was a significant reduction in spasticity at the wrist and fingers associated with a greater range of passive movement at the wrist and less finger curl at rest. There was a tendency for a further reduction in spasticity at elbow and wrist to occur with increasing dose but not for finger spasticity or curl. Effects present at six weeks were lost by 12 weeks except for a small improvement in elbow range of movement at the 1,500 Mu dose. There was no change in upper limb disability but a significant increase in patients' global assessment of benefit. CONCLUSION: Botulinum toxin produced beneficial effects in spasticity and passive range of movement in the hemiplegic upper limb. Increasing the dose increased the magnitude of response for impairments in some muscle groups but had little effect on duration of response.

A patient with a chronic amnesic state resulting from bilateral paramedian thalamic infarction showed a pattern of retrograde amnesia not previously reported. Personally relevant autobiographical memory was profoundly impaired, whereas knowledge of famous people and public events was relatively spared. Furthermore, knowledge of famous people, including the ability to make accurate temporal judgements, was less affected than knowledge of public events. In addition, we have documented a severe and systematic distortion of personal memory. These findings are not compatible with current accounts of retrograde amnesia based either upon the type of information stored (e.g. episodic versus semantic memory), or upon simple storage versus access models. We propose an explanation based upon an interactive cognitive model in which the patient shows a disorder at the 'thematic retrieval framework' level of memory organization due to a disconnection of frontal and medial temporal memory systems.

The results of chelation treatment of 137 patients presenting with neurological Wilson's disease are described, together with the more commonly observed toxic reactions to the various drugs employed. Fifty-seven patients made an excellent response to treatment and became symptom free. Thirty-six patients made a good recovery, but were left with some minor neurological deficit. Twenty-four patients had a poor response: although the disease process was arrested they were left more or less disabled. Twenty patients died: nine had little or no treatment, but 11 died despite apparently adequate chelation therapy. There was no obvious reason for this failure. The liver copper level was estimated in six of these patients: it was still significantly elevated in only one, but in all four in whom it was possible to make the determination, the concentration of copper in the basal ganglia was in excess of 45 micrograms/g wet weight. It was not apparent why adequate therapy failed to remove copper from the brains of these patients. There was no obvious clinical, histological or biochemical indicator of failure to respond to treatment. Initial deterioration before improvement was seen in 30 patients: the prognosis for a useful recovery was not necessarily worse than that in patients who did not show this phenomenon.

The aim of this study was to define prognostic parameters for survival in patients with malignant germ cell tumours progressing after platinum-based induction chemotherapy with or without surgery. A total of 164 progressing patients (testicular: 83%, extragonadal: 17%) were identified out of 795 patients treated with platinum-based induction chemotherapy for metastatic germ cell malignancy with or without surgery. 'Progressive disease' included patients who had progressed after a previous partial or complete remission as well as patients who failed primary therapy. Salvage chemotherapy consisted of 'conventional' platinum-based chemotherapy. Prognostic factors for survival were assessed by uni- and multivariate analyses. The resulting prognostic model was validated in an independent data set of 66 similar patients. For all 164 patients the median time from start of induction chemotherapy to progression was 10 months (range: 0-99). Thirty-eight (23%) patients relapsed after 2 years. The 5-year survival rate for all progressing patients was 30% (95% confidence interval 23-38%). In the univariate analysis the following factors most importantly predicted a poor prognosis: progression-free interval < 2 years: initial poor prognosis category (MRC criteria), < CR to induction chemotherapy, initial treatment early in the 1980s and treatment given at a 'small' centre. Three prognostic factors remained in the multivariate analysis: progression-free interval, response to induction treatment and the level of serum human chronic gonadotrophin (hCG) and alpha fetoprotein (AFP) at relapse. One hundred and twenty-four patients could be classified on the basis of these characteristics, Those patients with progression-free interval < 2 years, < CR to induction chemotherapy and high markers at relapse (AFP >100 kU l(-1) or hCG >100 IU l(-1)) formed a poor prognosis group of 30 patients, none of whom survived after 3 years. Patients with at most two of these three risk factors formed a good prognosis group of 94 patients (76%) with a 47% (37-56%) 5-year survival. Thirty-eight patients from the good prognosis group with a progression-free interval of >2 years had a 2-year survival of 74% (60-88%) and 5-year survival of 61%. These prognostic groups were validated in the independent data set, in which 5-year survival rates in the good and poor risk groups were 51% and 0% respectively. One-third of patients progressing during or after platinum-based induction chemotherapy for metastatic germ cell malignancy may be cured by repeated 'conventional' platinum-based chemotherapy. Good prognosis parameters are: progression-free interval of > 2 years, CR to induction treatment and normal or low serum markers at relapse (hCG < 100 IU l(-1) and AFP < 100 kU l(-1)). The results of high-dose salvage chemotherapy should be interpreted on the background of these prognostic factors.

VHL disease is a dominantly inherited familial cancer syndrome with variable expression and age-dependent penetrance. The diagnosis of isolated cases is often delayed compared with familial cases, and estimates of the new mutation rate have varied more than 20-fold. To investigate the frequency and origin of de novo VHL gene mutations we have analysed: (i) families with identical mutations to determine if there is a common haplotype, and (ii) apparent new mutation cases to determine whether the clinical diagnosis of such cases is reliable and to define the parental origin of de novo VHL gene mutations. Haplotyping of 12 VHL mutations occurring in two or more families (total 42 kindreds) revealed that for most mutations there was no evidence of a founder effect. A marked bias for a paternal origin of new mutations has been reported in other familial cancer syndromes such as neurofibromatosis type 1 (NF1), multiple endocrine neoplasia (MEN) 2B and bilateral retinoblastoma, but it is unclear whether this bias results from a greater susceptibility for mutagenesis during male gametogenesis because of the larger number of cell divisions compared with that in oogenesis, or from genomic imprinting effects. Analysis of 13 de novo VHL mutations in which the parent of origin could be established, showed no evidence for a bias for a paternal origin (seven paternal, six maternal), and differed significantly from that reported in NF1, MEN2B and bilateral retinoblastoma. This result demonstrates that an increased susceptibility to paternal allele mutation is not a universal finding in autosomal genetic diseases and that the origin of new mutations may be influenced by both genomic imprinting effects and the increased number of cell divisions in spermatogenesis compared with oogenesis.

A 5% aqueous solution of degraded carrageenan derived from the red seaweed Eucheuma spinosum was fed to guinea pigs in their drinking water over a period of 20-45 days. Occult blood in the faeces and multiple ulcers in the caecum, colon and rectum occurred in 100% of animals by the 30th day. The clinical and pathological features bear a close resemblance to human ulcerative colitis. The method provides a simple experimental model for the study of various aspects of the pathology of ulcerative lesions in the large intestine as well as the effects of therapeutic agents.

Thirty patients with acute, painful vertebral compression fracture were studied. Certain vertebrae, namely T8, T12, L1 and L4, were more likely to fracture. The majority occurred spontaneously (46%) or after trivial strain (36%). Of the former, 30% occurred whilst in bed. Radiation to the flanks and anteriorly was common (66%) but leg radiation was uncommon (6%). Associated symptoms noted were: nausea (26%), abdominal pain (20%), chest pain (13%). Straining exacerbated pain in only 60%. The position of comfort was lying flat (43%) or sitting (36%) but 16% found standing or walking most comfortable. The correct diagnosis was made at the first visit in only 43% of patients. In the remainder there was a mean delay of 4.5 days before diagnosis. This poor diagnostic rate may be improved if other clinical features of osteoporosis such as kyphosis and a previous history of wrist and hip fractures are recorded, particularly when acute back pain occurs in bed. Full thoracic and lumbar X-rays may be required because pain and site of pathology may not coincide. Bone scanning may be necessary if immediate X-rays are normal. In early management the position of most comfort may be preferable to complete bed rest.

A definition of rectal cancer is important for optimal planning of neoadjuvant therapy and surgical strategy. Anatomically the rectum is distal to the sigmoid colon and its upper limit is the termination of the sigmoid mesocolon. A commonly used definition is an adenocarcinoma with a distal margin at or below 15 cm from the anal verge, measured by rigid sigmoidoscopy. Standard anatomical texts put this at the level of the third sacral vertebra (Williams & Warwick, 1980) but it is generally agreed by surgeons that the rectum starts at the sacral promontory (UKCCCR, 1989). Whilst there remains debate about the proximal limit of the rectum, there is increasing recognition of the complexity of management of low rectal cancers. The Low Rectal Cancer Development Program (LOREC) has defined a ‘low’ rectal cancer as an MRI-based anatomical definition of an adenocarcinoma with its lower edge, at or below the origin of the levators at the pelvic side-wall. This usually corresponds to a measurement of within 6 cm of the anal verge (PELICAN Cancer Foundation; Salerno et al., 2006a, 2006b). A low rectal cancer should be defined as an MRI-based anatomical definition of an adenocarcinoma with its lower edge, at or below the origin of the levators at the pelvic side-wall. This usually corresponds to a measurement of within 6 cm of the anal verge. Recommendation grade D The Clinical Guidelines published by NICE (CG 131) in November 2011 defined three broad categories of rectal cancer, relating to the risk of pelvic local recurrence (LR) following and a for for and Clinical The of of the et al., has a in of rectal The ‘low’ and be as or the surgical margin is The risk is at risk of surgical margin of be the and the risk at risk of is the of the and below or or and or in the surgical margin is or the surgical margin or the of a or margin or low the or with margin defined as from the surgical margin is an of to et al., et al., et al., and et al., et al., The be by or and & The risk of is to the of et al., et al., recurrence a from to pelvic et al., with or the of and be a of et al., is the for of The of is for optimal and to management et al., et al., A the of has a for of remains to with and be by the of et al., of by a at risk of local and recurrence et al., et al., et al., This has by the risk cm from the anal verge and A and et al., that for of for and et al., and to as in the of with rectal cancer for should by there Recommendation grade should be as of and of Recommendation grade should be by the in the of the and and of to the management of the Recommendation grade D should with Recommendation grade D and for rectal cancer should be and by the within to Recommendation grade of with to has in a in rectal cancer at The rectal cancer a of and that with an following be to local that to the rectum and management of is to be in there is as to the definition of A that is a rectal cancer with that be the rectum, and that a risk of local et al., as this limit the of rectal the of of the of rectal and risk of Rectal as a from to The by to by of and of A rectal is defined as a in is be or in & to and or that to the optimal for rectal cancer is Recommendation grade D with rectal cancer the to in that the for rectal Recommendation grade D with the of rectal and it is important that in the and of should to local of rectal is A of with to cancer within the and of local is by surgical and the of A as an important for with to of or the and of rectal and to in and to a and and of NICE (CG 131) of rectal cancer with rectal should be to Recommendation grade with rectal be for rectal should to an rectal cancer for and Recommendation grade D A rectal is an adenocarcinoma within a in the the but the (Williams et al., This is an following or to be rectal and generally with an the of recurrence and of within of the margin as but that the risk of recurrence is is at the margin or within et al., for of and to to of important anatomical by the and surgical as and of by is important as of be to rectal cancer following local should be with pelvic this to the for by should be as for cancers. of rectal should be as this the of and of Recommendation grade Standard is an for rectal and of local or et al., of a rectal a in of a of following for rectal cancer is for to for et al., et al., of anal pelvic and and and rectal be the with low and et al., et al., for of the rectum and its and for and cancers. and local lower with a of with in a of et al., from to for and to for following et al., et al., and a of of or and is with recurrence in et al., et al., of is of local following local The risk of with of for the risk from to for for and for et al., of from to for to for and to for et al., is of recurrence and following local by the risk of from the et al., of and the of as for The of in or the of rectal or of the risk with of following The risk of following local has to be within the of by and its and a risk of is but a risk of to the of et al., and important in and there is the of of with et al., to be to should in is the of for this of the of The of of and for the of local for (Williams et al., and of that be in this of cancer, is with in in and of of et al., The of for of is et al., This the of in and of be a for in optimal with to the of with should be in to Recommendation grade with of or to low local recurrence and be of Recommendation grade local be at an risk of should be for This is to et al., et al., and is to for be to as the in of and of et al., it is that and be to of as et al., is of local from a to of local as of the and of the to the pelvic side-wall. be for or to the of in recurrence risk following local remains et al., et al., and of the risk of following local be to of at the in to the of the of et al., the optimal remains at with at and to at for is generally local with should be with or should be to the of in this by by Recommendation grade local should be a defined to at the and sigmoidoscopy. Recommendation grade et with a the and the and The of an that be the with local with and the of at to the of and local as for The et al., and et al., the and of and for of et al., et al., the of with of of with low of but that A of a of with for with in and low recurrence and low et al., The the of with and rectal by is to The with of three rectal with and or rectal with and This to in the and to in lower pelvic the rectal of with or has in the of rectal be in as for to The of in remains the of or be in with rectal cancer or and to The of and local in with rectal cancer, for remains the of Recommendation grade for is with as the or with a of pelvic for or cm et al., low et al., of to the in its remains with a of et al., NICE has that in for is the and of for rectal cancer is to its in for but to an the the of is the is for and Clinical to should be a a and a with in local should be of to with should be to a at the of in with et al., the of following a in to the with in and et al., A a to an has to in and in to this in the et al., The of by NICE that the of this for rectal cancer and its in for and Clinical but there is that it used as a to rectal be for rectal following in for or Rectal be for following or for et al., is a for with rectal cancer as an to for for or for for but This should be with the in for and as by NICE Recommendation grade et al., Cancer a & and a et al., of the of to a of with and of rectal cancer but of in the by of with Cancer to the be by of in or by a of of in is used to or the to surgical and be by as is usually of to for to a lower of a by is for the following The and for or The Rectal Cancer defined in the et al., Rectal Cancer the of to with and and with in the management of rectal cancer in a of with as low as & et al., This the of there for in to to this the Cancer et al., et al., and the et al., by or by or in to a the a in but in The of the risk of from to and from to at in in to a The of to an following and at risk of et al., is The risk of with this is at et al., The et al., et al., and the et al., with in and low rectal cancers. in to in a in a in that with to with the in an in and the of in and an in or and has in and has to be to in for rectal cancer et al., et al., with in rectal The by with by at in with low rectal et al., third of in with in the with for this or et al., The and 6 with at and in with or rectal cancer et al., in or of in rectal cancer that the of is with in of local but with cancer or Cancer The at 6 and with and in with rectal cancers. with and with lower and et al., there in or et al., of in et al., of or by risk et al., et al., Rectal Cancer is of there is that and is in et al., there to be or et al., of in but in is in et al., grade of is in et al., is with or in the and the et al., et al., published following and following as to or or and and and et al., et al., et al., in be to and The that to and with there in or et al., a in and in and et al., The of a The that the in The for this the but with the of et al., A in in of pelvic et al., The grade with to and et al., with the in or et al., and the in et al., or et al., The of for has the of the to the and and at risk of an et al., et al., The that a with and as & of in and be et al., but et al., et al., and the of to with to that as neoadjuvant therapy or as a for recurrence risk et al., et al., et al., or the and the risk of by and the remains with the to from to and the of there is risk of or of of and with a risk of a and in rectal from to and to with The with in of rectal is to for the and to of in as as as this with The of with rectal cancer the be at a low risk of following the a with a et al., et al., et al., optimal with rectal cancer the should be to Recommendation grade with rectal cancer the with a risk of or be for to local this by or by Recommendation grade A should be within from the of to risk of be within this and the has should be Recommendation grade should be of A of at in with or is Recommendation grade a in to this should be and to be at risk of as should be for A of at in with is Recommendation grade A to the of the Rectal Cancer with or to by or and a of with Rectal Cancer The of to the of the rectal cancer, and to the at risk of an and of local to be to be neoadjuvant in an to this the of with a of or by is This is and and to that this of the is The of to the and its of neoadjuvant therapy and remains The of in the of is to in an et al., a is of from the that to with of a and the et al., A of from of with or rectal a following et al., The of by a to in in rectal of with from in et al., to in et al., but to with is an & et al., in this of or with in and in The is the of with the the Cancer and for Clinical that a is at and The planning within the has by for the and as the of by the therapy is to be to but with with rectal cancer or the should be for to the of a this the is by A of at in with or is Recommendation grade with rectal cancer or the and to should be by to for Recommendation grade should be with and and the of the of and Recommendation grade should be and to as the Recommendation grade D of rectal in the lower rectum, commonly defined as a with its lower or the origin of the levators at the pelvic usually to within 6 cm of the anal verge is that low rectal the for and for and for with a risk of and at and a risk of and with and upper rectal et al., This is to of the to of the and of The is and The is that there is a and to management for a low rectal cancer the for a the surgical the of neoadjuvant and a low in anal and with a of et al., The and with the with at this level at the distal to as a to cancer an rectal the and of the and by an the lower rectum, and and et al., et al., et al., and for neoadjuvant therapy to et al., in et al., et al., and a of by neoadjuvant for et al., has that surgical be by a with in is an et al., The Low Rectal Cancer Development by of from and published et al., low rectal cancer but of an of is to the of to and to be the the is the of with a low rectal cancer an with a surgical to The of surgical is that a distal and margin in the of an low rectal cancer generally an but an of the and the the that be with the in the or & an is an the is and is or The is and the is with with in in is a and there is to an to as a et al., a et al., or a surgical et al., et al., is debate as to the for to the to a of the in of The following in to in the and The of low rectal in the optimal surgical should be by pelvic Recommendation grade The of and or by at or in low rectal should be the NICE 2011 risk Recommendation grade a low rectal cancer the level of the anal is the or the be A and be this is an or should be Recommendation grade a low rectal cancer the level of the anal is from the or or the an should be is an anatomical surgical the of the and the of is to the and the This is generally by and an Recommendation grade a low rectal cancer at the level of the is the or the of the the be the as an or Recommendation grade a low rectal cancer at the level of the the of the or or the to the an should be This is generally by and an Recommendation grade the of with or local pelvic this has to or increasing surgical the of and local pelvic recurrence is to as the of to increasing the of and neoadjuvant to the of as as in the & A of and an of a as a et al., that the be with of and the of a to the et al., but as the is the of to in rectal to or et al., et al., et al., et al., and et al., published as the et al., and et al., The with with and and in or et al., The by of with or The of from to et al., the of is to the of to the and and the of The et al., and 6 et al., in in cancer for and and from the et al., of to as in et al., & this is an for A of the of neoadjuvant to and lower to with a risk of The and used of A in with et al., et al., et al., The of lower and et al., The that to and is with a et al., A by with 6 of neoadjuvant in with or et al., there in local and or a in in the neoadjuvant a to the with of following in the in the in and in the The is of by and a of and of is that of following be following it be to et al., in of and & in with low rectal a following a of with within cm of the anal verge, a and of et al., it is in low rectal be to of the or upper rectum with of in the A of with rectal cancer a in within a local with of with in the by and a et al., A the of in a and a Cancer in with low rectal cancer is the of in with low rectal the for has in A and in a and is a and to be this remains a management and that this should be as an to remains within the as is and by local and with a and be A defined as used in is to local at the Recommendation grade an increasing in the management of cancer and has to the in the The of should be agreed by the and should be within to The of therapy should be by the and the the risk for and of the and the for of has that and in colon for and the of in rectal of and to be as as and for therapy et al., et al., for its the is the level of is to NICE has for for and The of to in recurrence risk et al., et al., and et al., with NICE has for this for and from the has a in but in et al., the of should be the and of the a should be an as risk of from cancer risk of from The to be in as the of is the of with at a of from the of to et al., from the that the to et al., this be at the of with risk of from and of the is A of as in colon cancer, et al., et al., and et al., in or a of or the the of a of with the 6 of is to neoadjuvant is a of in and cancers. The is the of neoadjuvant in defined colon cancer is the of in in The to the of in to be at lower risk of The with to or of risk of recurrence by and by et al., of within the a but by et al., is or in with for and there be to its in with with in or and to a in colon to et al., with from that is a for the of from et al., et al., The of the of by or by for the in for to and low risk in to with about the and of and and for the et al., The recurrence risk of colon is generally with a of the of in this of it is to be of by NICE 131) for and is to local of the with with or pelvic a of with rectal cancer in and with et al., the of optimal and The following to a of that or from et al., to the of in rectal cancer, and from and of to be in of a low and from a and to to and and of and of and the and of to with or should be as for the of with cancer following Recommendation grade A a should be an Recommendation grade A with cancer should be for Recommendation grade A or should be to with the with cancer and for Recommendation grade recurrence of should be for in the of a in is with and in with the and the to is commonly in rectal but in colon cancers. The of and a to of surgical with or from following of is et al., et al., with from surgical remains is a for with the of surgical The and to in with et al., a in The a of with with the of to This it that the of in a an et al., as a or from in this to as and with neoadjuvant but remains from and to the of to in with for and Clinical should be by the in the of a following and surgical should be for at to of for the of an in cancer A of and the of and the to for and is a a of in of and for with of and et al., A of of in the of with with in or of The and and of to and low and by NICE as for for and with or to in and NICE the of three of the and and as has to be for and in in three of used in the of & with or a from with to be to and to of in the et al., this it that a of with from a of therapy this in The has a in of and and and to et al., a is for as a for or The and NICE 131) has the of for and used in with an to has to and used in to et al., and and et al., et al., there is of in this therapy et al., is by NICE for and a and has to in with and in the et al., but is by NICE for and and in with the of to and in the of and in et al., et al., but in et al., of to as therapy et al., and as a in the et al., et al., has and is and has used in to an as therapy et al., in to an as therapy et al., and as a in the et al., et al., and and The and in the and to in et al., The of and has to and NICE for to be used in with or for with for and for and Clinical the in this of has by NICE and is NICE and to be used in with or in cancer as a for and The is the to the and in with in the a in the of et al., there in or is a has a in the et al., has by NICE and has The an of a and a with a in with a in et al., NICE has the of as a within the an agreed for and with or or should be in the with a and to and to a of management to the of of Recommendation grade with should be by the and should be to an for of Recommendation grade and with cancer should it a to with and Recommendation grade D with cancer should be in in the of and cancer Recommendation grade D is important that with cancer the to and to important at should be as an of Recommendation grade D is defined as the of with of and and of and is The of is of the of for and of in the of the in with for and Clinical is of cancer, in the of be by of this in the of the in with as in the NICE in of and to and et al., et al., the as a but has is defined the and to with cancer and of it from the of and to or and the to the of and to as as with the of the for and Clinical is from in three it should at of the cancer the of the and by the of it is with as and as as as and and for to it is that cancer and should be to cancer at of Recommendation grade D The for in has for of to optimal of The for to the the of the of et al., cancer and as as the of and with from and it important for to to and is that and of and an and to et al., and from to the cancer by of the by and to to or or an of and should to et al., should be with for and Recommendation grade cancer there is a to to the of Whilst this for by or in to be or to as for and and or the cancer and and of in cancer but there is in and to et al., the of and the Cancer in has to a of of and for cancer should be to with about to from in a to and to the be to as and for the and of of and cancer should to Recommendation grade D of cancer should be for of and be as Recommendation grade is of the of but the is from it is by the that the has or of the of remains and in and be and with to the for should be to to a of of of of of an in and that and for at the of et al., about of should be with and in the of cancer in is for of of or at the of should at the be the of for and this with and This to be and with the and The of of that the of of an to the of The that by the it that a the the and an and or the of to but or in an to by or be to should to about the and of in a as and in the of to of the and and with cancer the of should be and to Recommendation grade cancer at the of should be and to in a as as Recommendation grade D with cancer should to of the in Recommendation grade D The has a of of and by or local and at from cancer or and The from the be a in or as or in should be to local to of within in of a and a to a remains and generally of to with local in to of and for with cancer should the to Recommendation grade D The NICE for of the in the of the to be to and of but of that or for and Clinical about and the of and by the management of and and in the and and the of The NICE that for and and for should be and in a as there has to in to this or or increasing or the for for The of should be in and be as the for with and from cancer be at for or for with for and of and should be an to and of the for is the to of or in the Recommendation grade has a for has a for NICE low for rectal has from and and a of the of has by the of as for and cancer and has of the Cancer for and The to

With advances in the identification and molecular taxonomy of Aeromonas spp., these organisms, which are widely distributed in the environment, are increasingly being recognised as human pathogens. Clinical infections include gastroenteritis, skin and soft tissue infections and bacteraemia. Antibiotic resistance poses a potential problem in the antimicrobial therapy of infections cased by Aeromonas spp. While most strains are susceptible to chloramphenicol, ciprofloxacin, co-trimoxazole and the aminoglycosides, the activity of amoxycillin/clavulanate and the acylureidopenicillins is inconsistent. Addition of a beta-lactamase inhibitor does not significantly enhance the activity of the acylureidopenicillins. Aztreonam and the carbapenems, imipenem and meropenem remain highly active. Although resistance to the first and second generation cephalosporins is variable, more than 90% of Aeromonas spp. are susceptible to the third generation agents. Of potential significance is the identification of chromosomally-encoded inducible beta-lactamases, associated with resistance to extended spectrum penicillins, cephalosporins, monobactams and carbapenems, in clinical isolates of Aeromonas spp. Two distinct enzymes are produced: the A1 enzyme, a serine beta-lactamase behaving as a group 1 cephalosporinase, and the A2 enzyme, a metallo beta-lactamase which hydrolyses a wide range of beta-lactam agents including the carbapenems. The clinical relevance of these enzymes in Aeromonas spp. is unclear.